Pharmacological properties of substituted gamma-butyrolactones. I. The effects on the central nervous system.
D000661:Amphetamine / Q000494:pharmacology; D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001463:Barbiturates / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002087:Butyrates / Q000494:pharmacology; D002110:Caffeine / Q000037:antagonists & inhibitors; D002375:Catalepsy / Q000139:chemically induced; D002490:Central Nervous System / Q000187:drug effects*; D002746:Chlorpromazine / Q000037:antagonists & inhibitors; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D007928:Lethal Dose 50; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D012890:Sleep / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects; D014149:Tranquilizing Agents / Q000494:pharmacology*
D000777:Anesthetics; D001463:Barbiturates; D002087:Butyrates; D007783:Lactones; D014149:Tranquilizing Agents; D002110:Caffeine; D000661:Amphetamine; D002746:Chlorpromazine